• Bone turnover markers were lower with prednisolone, indicating slower bone turnover compared with hydrocortisone.
• Modest cardiometabolic improvements were observed, including reductions in weight, body mass index, waist circumference, and glycated hemoglobin.
• Safety and quality of life were similar between treatments, with no adrenal crises reported during the study.
• Clinical impact remains unclear, as changes in bone markers were small relative to antiresorptive therapies and outcomes were limited to surrogate measures.

Source: JAMA Network Open